Milo Ventimiglia

Milo Ventimiglia

Ask VT AI
View News Summary
  • Celestica beats Q3 estimates, raises guidance, and launches NCIB, driven by strong AI and data center demand.
  • Incyte advances multiple early-phase cancer trials with potential therapeutic breakthroughs, highlighting their strategic focus on oncology and rare diseases.
  • Trump and Japan's Takaichi sign critical minerals supply deal to reduce China's dominance and bolster U.S.-Japan alliance.
20 days
USA flag

United States Politics

Discover the latest news, candidates, 
and key topics of US politics

Latest News
Ask VT AI
View News Summary
  • Celestica beats Q3 estimates, raises guidance, and launches NCIB, driven by strong AI and data center demand.
  • Incyte advances multiple early-phase cancer trials with potential therapeutic breakthroughs, highlighting their strategic focus on oncology and rare diseases.
  • Trump and Japan's Takaichi sign critical minerals supply deal to reduce China's dominance and bolster U.S.-Japan alliance.
20 days
USA flag

United States Politics

Discover the latest news, candidates, 
and key topics of US politics

Most Reported By
News from Milo Ventimiglia